Olema Pharmaceuticals announces participation in investor conferences discussing advances in breast cancer therapies and company updates.
Quiver AI Summary
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer, has announced its participation in several upcoming investor conferences. These include the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11, 2026, the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. All sessions will feature a fireside chat format and will be available for live streaming and recording on Olema's investor relations website. Olema is advancing novel therapies, including its lead candidate palazestrant (OP-1250) and the KAT6 inhibitor OP-3136, to improve treatment outcomes for patients with breast cancer.
Potential Positives
- Olema Pharmaceuticals is participating in multiple prominent investor conferences, which increases visibility and potential interest from investors in the company’s pipeline.
- The company's lead product candidate, palazestrant (OP-1250), is currently in two Phase 3 clinical trials, indicating advanced development stages and potential for future commercialization.
- Olema is expanding its pipeline with the development of OP-3136, a KAT6 inhibitor now in a Phase 1 clinical study, showcasing the company's commitment to innovation in cancer therapies.
Potential Negatives
- Olema Pharmaceuticals is in a clinical stage, which typically carries high risks associated with the uncertainty of drug development and potential failure in clinical trials.
- The announcement focuses solely on upcoming investor conferences without addressing any recent developments or progress in their clinical trials, which may raise concerns about the company's current status and future prospects.
- Participation in investor conferences does not guarantee successful investment interest or positive market responses, indicating potential challenges in attracting investors.
FAQ
What events will Olema Pharmaceuticals participate in?
Olema Pharmaceuticals will participate in three upcoming investor conferences: Guggenheim Securities, Citi's 2026 Virtual Oncology Summit, and Oppenheimer's Healthcare Conference.
When is Olema's presentation at the Guggenheim Securities Summit?
Olema's presentation at the Guggenheim Securities Emerging Outlook: Biotech Summit is scheduled for February 11, 2026, at 10:00 a.m. ET.
How can I access Olema’s conference presentations?
Live webcasts and recordings will be available on Olema’s investor relations website in the Events and Presentations section.
What is Olema's lead product candidate?
Olema's lead product candidate is palazestrant (OP-1250), an orally available complete estrogen receptor antagonist currently in two Phase 3 trials.
Where is Olema Pharmaceuticals headquartered?
Olema Pharmaceuticals is headquartered in San Francisco, with additional operations in Cambridge, Massachusetts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OLMA Insider Trading Activity
$OLMA insiders have traded $OLMA stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.
Here’s a breakdown of recent trading of $OLMA stock by insiders over the last 6 months:
- IAN T CLARK has made 0 purchases and 3 sales selling 264,800 shares for an estimated $7,873,109.
- NASEEM ZOJWALLA (Chief Medical Officer) has made 0 purchases and 4 sales selling 269,509 shares for an estimated $7,530,147.
- DAVID C. MYLES (CH. DISCOV. & NON-CLIN DEV OFF) has made 0 purchases and 8 sales selling 161,000 shares for an estimated $4,660,772.
- SHANE WILLIAM CHARLES KOVACS (CH. OPERATING & FINANCIAL OFF.) has made 0 purchases and 2 sales selling 103,822 shares for an estimated $2,980,054.
- CYRUS HARMON has made 0 purchases and 7 sales selling 41,370 shares for an estimated $657,435.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OLMA Hedge Fund Activity
We have seen 71 institutional investors add shares of $OLMA stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MPM BIOIMPACT LLC removed 2,378,762 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $23,288,079
- WOODLINE PARTNERS LP removed 1,288,000 shares (-36.7%) from their portfolio in Q3 2025, for an estimated $12,609,519
- PICTET ASSET MANAGEMENT HOLDING SA removed 1,133,804 shares (-69.3%) from their portfolio in Q4 2025, for an estimated $28,345,100
- JENNISON ASSOCIATES LLC added 963,997 shares (+inf%) to their portfolio in Q4 2025, for an estimated $24,099,925
- MILLENNIUM MANAGEMENT LLC removed 939,636 shares (-73.9%) from their portfolio in Q3 2025, for an estimated $9,199,036
- SILVERARC CAPITAL MANAGEMENT, LLC added 933,541 shares (+inf%) to their portfolio in Q3 2025, for an estimated $9,139,366
- UBS GROUP AG removed 897,094 shares (-75.3%) from their portfolio in Q4 2025, for an estimated $22,427,350
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OLMA Analyst Ratings
Wall Street analysts have issued reports on $OLMA in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- Piper Sandler issued a "Overweight" rating on 01/07/2026
- Citigroup issued a "Buy" rating on 12/12/2025
- Goldman Sachs issued a "Buy" rating on 11/21/2025
- JP Morgan issued a "Overweight" rating on 11/18/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/18/2025
- Oppenheimer issued a "Outperform" rating on 11/18/2025
To track analyst ratings and price targets for $OLMA, check out Quiver Quantitative's $OLMA forecast page.
$OLMA Price Targets
Multiple analysts have issued price targets for $OLMA recently. We have seen 7 analysts offer price targets for $OLMA in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Michael Yee from UBS set a target price of $45.0 on 01/07/2026
- Yigal Nochomovitz from Citigroup set a target price of $60.0 on 12/12/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $45.0 on 12/11/2025
- Matthew Biegler from Oppenheimer set a target price of $48.0 on 12/11/2025
- Richard Law from Goldman Sachs set a target price of $38.0 on 12/11/2025
- Anupam Rama from JP Morgan set a target price of $32.0 on 11/18/2025
- Brad Canino from Guggenheim set a target price of $20.0 on 10/08/2025
Full Release
SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
Guggenheim Securities Emerging Outlook: Biotech Summit
Date and Time: February 11, 2026 at 10:00 a.m. ET
Format: Fireside Chat
Location: New York, NY
Citi’s 2026 Virtual Oncology Leadership Summit
Date and Time: February 19, 2026 at 1:00 p.m. ET
Format: Fireside Chat
Location: Virtual
Oppenheimer 36
th
Annual Healthcare Life Sciences Conference
Date and Time: February 26, 2026 at 8:00 a.m. ET
Format: Fireside Chat
Location: Virtual
Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at
ir.olema.com
.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit
www.olema.com
.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]
